IMPACT OF PSORIASIS ON DEVELOPMENT OF LONG-TERM ENDPOINTS IN PATIENTS WITH CORONARY HEART DISEASE

Psoriasis is a chronic immune-related skin disease that not only affects the epidermis, but also contributes to the development of cardiovascular diseases, in particular coronary heart disease (CHD).

The objective was to compare the incidence of adverse cardiovascular events in patients with psoriasis and combinations of CHD and psoriasis in the long term.

Material and methods. 112 patients were studied (60.0 (57.5; 63.5) in 3 groups: 1st - CHD, 47 patients; 2nd - psoriasis, 52 patients; and 3rd - CHD + psoriasis, 13 patients) by risk factors of developing the long-term adverse endpoints in 1 year. The endpoints included hospitalization in case of exacerbation of psoriasis, for cardiovascular reasons, deaths, strokes, and myocardial infarctions.

Results. The CHD and CHD + psoriasis groups did not differ in terms of risk factors, except for the higher incidence of diabetes mellitus in the CHD group (p = 0.021). When comparing the 1st and 3rd groups, arterial hypertension was more common in group 3 (p=0.007), and 1 year after, hospitalizations for all causes (p<0.001) and strokes (p=0.044) were more common in the same group. Conclusion. The presence of psoriasis in combination with CHD significantly increases the risk of hospitalization and stroke in patients in the long-term period.><0.001) and strokes (p=0.044) were more common in the same group.

Conclusion. The presence of psoriasis in combination with CHD significantly increases the risk of hospitalization and stroke in patients in the long-term period.

1. Brynina A. V. Clinical and anamnestic features of psoriasis and coronary heart disease in individuals with comorbidity. Journal of Grodno Medical University. 2016;(4):81-85. (In Russ).

2. Bulanov E.A., Mal G.S., Silina L.V. Some features of cardiovascular kontiniuuma in patients with coronary heart disease and psoriasis. International Journal of Applied and Basic Research. 2015;(10):84-86. (In Russ).

3. Kungurov N.V., Filimonkova N.N., Tuzankina I.A. Psoriatic disease. Ural University Publishing House. 2009:248. (In Russ).

4. Mal G.S., Silina L.V., Bulanov E.A. Cardiovascular continuum in patients with psoriasis complicated by ischemic heart disease. Symbol of Science: International Scientific Journal. 2015;(7):145-147. (In Russ).

5. Mordovtsev V.N. [et al.] Skin diseases with hereditary predisposition. 2002:260

6. Parfenova M.A., Bobyntsev I.I., Silina L.V. Indicators of lipid peroxidation and the antioxidant defense system in patients with psoriasis and coronary heart disease during complex treatment with Mexicor. Kursk scientific and practical bulletin “Man and his health”. 2012;(4):70-73. (In Russ).

7. Smirnova I.O., Vladimirova I.S. Psoriasis and cardiovascular comorbidity (literature review). Medical alphabet V.N. 2020;(6):18-21. (In Russ).

8. Khismatullina Z.R. [et al.]. Psoriasis, psoriatic arthritis, metabolic disorders and cardiovascular diseases. What common? Klinicheskaya Dermatologia I Venerologia. 2020;19(2):137-145. (In Russ).

9. Gorga Е. [et al.]. Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study. Monaldi Arch Chest Dis. 2018;(88):15-19.

10. Husted J. [et al.]. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care & Research. 2011;63(12):1729-1735.

11. Takeshita J. [et al.]. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;(76):393-403.

12. Joshi АА. [et al.] Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis. JAMA Cardiol. 2018;3(10):949-956.